Join
Live feed
·
PRReleasevia Quantisnow
Compugen Ltd. logo

Compugen to Host Conference Call to Discuss Exclusive License Agreement with Gilead for COM503, Novel Immuno-Oncology Pre-Clinical Program Harnessing IL-18 Biology

ByQuantisnow·Wall Street's wire, on your screen.
CGEN· Compugen Ltd.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track CGEN (Compugen Ltd.) and more on Quantisnow.